Finding a Way Through M&A

Total Page:16

File Type:pdf, Size:1020Kb

Finding a Way Through M&A RESEARCHNovember REPORT18, 2019 FindingNovember a Way through18, 2019 M&A Stock Rating HOLD Price Target CAD $123.58 Current Price CAD $140.49 Bear Price Bull Case Target Case $107.75 $123.58 $139.41 Ticker DHR Danaher Corporation Market Cap (MM) $102,707 Finding a Way through Market Cap/LFCF NTM 33.5x M&A EV/EBITDA NTM 22.5x 52 Week Performance After conducting an analysis of the Medical Devices space at large, the Healthcare Team decided that Danaher Corporation’s ability to 120 effectively use inorganic growth as a competitive advantage warrant a further look. This report outlines various elements of Danaher’s business that we wanted to gain conviction on before reaching a 100 decision on the name. Overall, we believe that Danaher’s highly disciplined M&A strategy that incorporates the Danaher Business System (DBS) and philosophy 80 of detail-oriented accountability has demonstrated a proven ability to select, integrate and grow acquisition targets. Coupled with its current business, we believe that Danaher has strong fundamentals. 60 Despite our conviction in Danaher’s fundamentals, our price target of 27-Feb-17 29-Apr-17 29-Jun-17 $123.58 is much lower than their current price of $140.59. Therefore, DHR S&PS&P 100 Index the Healthcare Team has decided on a stock rating of HOLD. Industrials Laura Wu [email protected] Ruby Harris [email protected] William Cao [email protected] The information in this document is for EDUCATIONAL and NON-COMMERCIAL use only and is not intended to Tina Huang constitute specific legal, accounting, financial or tax advice for any individual. In no event will QUIC, its members or directors, or Queen’s University be liable to you or anyone else for any loss or damages whatsoever (including [email protected] direct, indirect, special, incidental, consequential, exemplary or punitive damages) resulting from the use of this document, or reliance on the information or content found within this document. The information may not be reproduced or republished in any part without the prior written consent of QUIC and Queen’s University. QUIC is not in the business of advising or holding themselves out as being in the business of advising. Many factors may affect the applicability of any statement or comment that appear in our documents to an individual's particular circumstances. © Queen’s University 2019 November 18, 2019 Finding a Way through M&A Table of Contents Company History and Overall M&A Strategy 3 Danaher Business System (DBS) Deep Dive 5 Segments Analysis: Overview of Key Segments 6 Environmental & Applied Segment: Hach Company 7 Life Segment: Subsidiaries Overview 9 Diagnostics Subsidiaries 11 GE Biopharma Acquisition: Deep Dive 13 Valuation 16 2 November 18, 2019 Finding a Way through M&A Company History and Overarching M&A Growth Strategy The history of Danaher adds a fair bit of colour to its Danaher could gain a competitive advantage through overall strategy as a company. Danaher Corporation operational excellence, or (2) bolt-on transactions, was originally founded in 1969 as a REIT; 9 years later, wherein complementarity of goods can be leveraged it reorganized itself as a new corporation, called or network effects through expanding market Diversified Mortgage Investors. It then entered into the coverage could be built. This highly principled and vehicle systems market, modeling most of its disciplined M&A strategy has allowed its operating operations after the Toyota Production system. It margins to grow an average of 2.8% faster than eventually expanded into many more markets, most revenue, indicating that with each acquisition it is able notably that of precision motion equipment, electronic to tighten its operations and parent them effectively. test tools, environmental water quality testing, power quality products and consumables manufacturing. After the acquisition is completed, an agile business- Since then, it has been aggressively expanding into the unit integration team takes over from the business medical devices space, gaining a sustainable footing development team responsible for M&A due diligence. amongst incumbents. All of these expansions have The business-unit integration team is responsible for been achieved through acquisitions, mergers or executing all of the ramp-up work to the acquisition takeovers. Since 1984, it has acquired hundreds of target’s normal operations, and ensures that the DBS businesses – more than 50% of Danaher’s total philosophy (and system, when appropriate) were revenue today has been acquired in the past 7 years, implemented successfully. The process of identifying a demonstrating that Danaher is well-versed in the target, conducting rigorous due diligence and execution of inorganic growth. integrating successfully ultimately led to the fundamental transformation of the company from an Highly Effective Serial Acquirer $845MM industrial goods manufacturer to a $12.6B global conglomerate. Danaher’s overarching operating model, called the Danaher Business System (DBS), is consistently applied EXHIBIT I across all business units. It measures performance in four key areas: quality, delivery, cost and innovation. Danaher Revenue Breakdown, 2002-2015 More than a tactical implementation of a technology, DBS has evolved into a company philosophy that demands rigorous, detail-oriented and measurable Environmental (15%) Environmental (7%) progress at every level. The operating model is built Water Quality (10%) upon the belief that unless well-managed, businesses Motion (21%) Industrial Tech (17%) with high average gross margins become self- destructive and encourage complacent practices. Measurement (15%) Measurement (17%) Applying DBS to newly acquired businesses is able to grow these margins. For example, after Danaher’s Dental (14%) acquisition of Tektronix (a test and measurement Tools (32%) equipment company), its margins increased by 15.8% within a year, and its sales grew by 14.9%. Life Sciences & Other (17%) Diagnostics (35%) Building on this, Danaher only acquires a business if it sees margin expansion potential, as well as if it serves 2002 2015 one of two purposes: (1) platform-establishing transactions (new market entry acquisitions) wherein Source: DHR Company Filings, RBC Capital Markets 3 November 18, 2019 Finding a Way through M&A Company History and Overarching M&A Growth Strategy Capital Allocation: Strong M&A Focus Management has traditionally financed acquisitions via cash on hand, by has also taken on debt to finance As would an astute value investor, Danaher has major acquisitions – whereas the GE Biopharma consistently bought companies trading at a discount acquisition raised their net debt-to-EBITDA to around (Exhibit III). In order to acquire these companies, the 3.9x, they have historically stayed at a steady 3.0x. proceeds from process improvements in previously- Management is communicated that this is a acquired business are used to fund new M&A. These comfortable net debt-to-EBITDA margin. Danaher’s proceeds are mostly unlocked through shared financial position is quite healthy – its 2018 free cash expertise in product engineering, supplier flow (FCF) value of $3.4B represented an increase of management synergies and labour productivity. This 16.5% vs. 2017, a FCF to net income conversion ratio has strengthened its position as one of the most of 127%. This marked the 27th consecutive year in acquisitive players in the “multi-industry” sector, which the FCF exceeded net income. Their dividends allocating almost 80% of balance sheet capacity on are modest, paying out only 0.6% of their net income M&A vs. the peer average of around 40%. when compared to their peers who pay out ~2.0%. EXHIBIT II Danaher’s M&A-Focused Capital Allocation 100% 80% 60% 40% 20% 0% 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Source: RBC Capital Markets M&A Capex Dividends Buybacks EXHIBIT III Danaher’s Capital Allocation Long term market norm 5.0x Sybron Dental 4.0x 3.0x Hach 2.0x Josiyn 1.0x American Lifeschultz Fluke Tektronix 0.0x Precision Enterprise Value to Gross Value Assets to Gross Enterprise 0% 5% 10% 15% 20% 25% 30% 35% 40% Source: DHR Company Filings Gross Business Return 4 November 18, 2019 Finding a Way through M&A Danaher Business System (DBS) Deep Dive Danaher Business System (DBS) including thorough application of every acquisition done to date by the parent company. Management Danaher’s operations, culture, managerial decisions and prides itself in the ability to swiftly integrate new acquisition performance is defined by the company’s businesses. Consequently, through DBS, management “Danaher Business System.” Operationally, DBS is can make acquisitions of familiar business models with similar to the “Toyota Way”. limited downside risk. DBS is run on the basis of improving cost structure by Through DBS, Hach has reduced its time to market expanding gross margins and lowering G&A as a down on average from 36+ months to 18 months, percentage of sales while reinvesting in top line growth which is beneficial to customers but also helps increase through strong customer relationships. The DBS the cycle time and cadence to producing new products. program is difficult to place a firm value on, but Since 2016, Hach’s product pipeline has increased by fundamentally represents management’s execution on 35% and the launch of products increased by 25%. all subsidiaries with five core values: quality of management, customer engagement, continuous improvement, product innovation, and focus on shareholder value. As such, it is representative of the EXHIBIT IV culture developed at Danaher. The culture appears to Danaher Glassdoor Review be well-received, as it was rated 3.5/5 stars out of ~400 reviews on glassdoor (Exhibit IV). Danaher has sales and service representatives in 60 countries to maintain customer relationships. DBS is designed to allow the sales team to remain accountable with respective call points, and facilitates new integration of businesses.
Recommended publications
  • Participant List
    Participant list Please find below a list of current participants in theAustralian Life Sciences Remuneration Review. For a complete list by super sector, sector and segment refer to Mercer WIN®. A. Menarini Australia B Braun Avitum Australia Cardinal Health AbbVie Australia Bausch & Lomb (Australia) Cepheid Abbott Australasia Baxter Healthcare Cochlear Acrux Bayer Coloplast Australia Alcon Beckman Coulter - Diagnostics Convatec (Australia) Alere Beckman Coulter - Life Sciences CooperVision Australia Allergan Becton Dickinson DH Dental Alphapharm Besins Healthcare Australia DSM Nutritional Products Amgen Biogen Idec Australia Device Technologies Aust Ascom Australia Biomerieux Australia Ecolab Aspen Australia Blackmores Edwards Lifesciences Astellas Pharma Boehringer Ingelheim Eisai Australia AstraZeneca Boston Scientific International Elanco Australasia Australian Nuclear Science and Technology Boucher & Muir Eli Lilly Australia Organisation (ANSTO) Bristol-Myers Squibb Evolution Health Australian Pharmaceutical Industries CSL Ferring Pharmaceuticals B Braun Australia © September 2020 Mercer Consulting (Australia) Pty Ltd Australian Life Sciences Remuneration Review 4.1 Participant list Fresenius Kabi Australia Integrated DNA Technologies (IDT) Merck Serono Fresenius Medical Care Australia Invisalign Australia Mindray Medical International GE Australia Healthcare Ipsen Molnlycke Health Care GN Netcom Australia J&J Pacific Mundipharma Galderma Australia Janssen-Cilag - Australia Nevro Medical Australia Getinge Johnson & Johnson Medical
    [Show full text]
  • Danaher Corp /De
    DANAHER CORP /DE/ FORM 10-K (Annual Report) Filed 3/15/2006 For Period Ending 12/31/2005 Address 2099 PENNSYLVANIA AVE N.W., 12TH FLOOR WASHINGTON, District of Columbia 20006 Telephone 202-828-0850 CIK 0000313616 Industry Scientific & Technical Instr. Sector Technology Fiscal Year 12/31 Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2005 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-8089 DANAHER CORPORATION (Exact name of registrant as specified in its charter) Delaware 59 -1995548 (State of incorporation) (I.R.S.Employer Identification number) 2099 Pennsylvania Ave. N.W., 12 th Floor Washington, D.C. 20006-1813 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area code: 202-828-0850 Securities Registered Pursuant to Section 12(b) of the Act: Title of each class Name of Exchanges on which registered Common Stock $.01 par value New York Stock Exchange Pacific Exchange Securities registered pursuant to Section 12(g) of the Act: NONE (Title of Class) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
    [Show full text]
  • 2019 Annual Report
    1984 2019 2019 MARKED DANAHER’S 35TH ANNIVERSARY To honor this milestone, the front cover of this year's annual report features the original Danaher logo and bright blue color palette. We proudly celebrate our company's history as the prelude to a 35 future filled with opportunity. By living our core values of building the best team, continuously improving, “ listening to our customers every day and driving innovation, we ultimately deliver long-term shareholder value.” Thomas P. Joyce, Jr. Financial Operating Highlights (dollars in millions except per share data and number of associates) 2019 2018 Sales $ 17,911.1 $ 17,048.5 Operating Profit $ 3,269.4 $ 3,055.1 Net Earnings $ 2,432.3 $ 2,406.3 Net Earnings Per Share (diluted) $ 3.26 $ 3.39 Operating Cash Flow $ 3,657.4 $ 3,644.0 Investing Cash Flow $ (1,166.1) $ (2,873.9) Financing Cash Flow $ 16,589.9 $ (797.4) Capital Expenditures $ (635.5) $ (583.5) Capital Disposals $ 12.8 $ 6.3 Free Cash Flow (Operating Cash Flow less Capital Expenditures plus Capital Disposals) $ 3,034.7 $ 3,066.8 Number of Associates 60,000 58,000 Total Assets* $ 62,081.6 $ 47,832.5 Total Debt ** $ 21,729.1 $ 9,740.3 Stockholders’ Equity $ 30,281.9 $ 28,226.7 Total Capitalization (Total Debt plus Stockholders’ Equity) $ 52,011.0 $ 37,967.0 * 2018 data includes both continuing and discontinued operations ** Long-Term Debt ($21,516.7 for 2019 and $9,688.5 for 2018) plus Notes Payable and Current Portion of Long-Term Debt ($212.4 for 2019 and $51.8 for 2018) All financial data set forth in this annual report relates solely to continuing operations unless otherwise indicated.
    [Show full text]
  • Eprocurement Small Order Process: Vendors with Item Catalogs
    eProcurement Small Order Process: Vendors with Item Catalogs Updated April 18, 2012 V000142495 ABCAM INC V000137051 ILLUMINA INC V000081265 ACO MEDICAL SUPPLY V000014509 INTERMOUNTAIN SCIENTIFIC V000125369 ACTIVE MOTIF V000080847 INTREX COMPUTERS INC V000112094 AFFYMETRIX INC V000006118 INVITROGEN CORPORATION V000114793 AGILENT TECHNOLOGIES INC V000130596 INVIVOGEN V000000082 ALLTECH ASSOCIATES INC V000005714 JACKSON IMMUNORES V000000118 AMRESCO V000001442 JACKSON LAB V000152997 ANASPEC INC V000001558 LABORATORY SAFETY V000132756 ASYLUM RESEARCH CORP V000047258 LABREPCO INC V000000126 ATCC V000108167 LEICA MICROSYSTEMS V000068824 ATLANTA BIOLOGICALS V000088788 LI-COR INC V000162435 ATLANTIC FITNESS V000111733 LIST BIOLOGICAL LABS V000000307 BASI V000002832 LONZA WALKERSVILLE INC V000000261 BD BIOSCIENCES V000149811 MATRIX TECH V000000259 BECKMAN COULTER V000135360 MEDICAL SPECIALTIES V000176191 BENCHMARK TECH V000022962 MIDWEST SCIENTIFIC V000101618 BETHYL LABS V000078901 MILTENYI BIOTEC INC V000159330 BIO BASIC V000008542 MOLECULAR DEVICES INC V000004901 BIOGENIX LABORATORIES V000001340 MP BIOMEDICALS V000145647 BIOLEGEND V000188293 NETA SCIENTIFIC INC V000157241 BIOLINE USA INC V000186184 NEWEAST BIOSCIENCES V000112934 BIOLOGICAL SPECIALTY CORP V000001880 NEW ENGLAND BIOLABS INC V000000303 BIO-RAD V000004850 NEWPORT V000000305 BIO-TEK INSTRUMENTS V000052248 NIKON INSTRUMENTS INC V000000349 BRAINTREE V000167597 OCEAN OPTICS V000190375 BUTLER SCHEIN V000001937 OLYMPUS AMERICA INC V000000429 CAMCOR V000139707 OPEN BIOSYSTEMS V000000454
    [Show full text]
  • 2017 INVESTOR & ANALYST DAY December 14, 2017
    2017 INVESTOR & ANALYST DAY December 14, 2017 Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, deterioration of or instability in the economy, the markets we serve and the financial markets, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify, consummate and integrate appropriate acquisitions and successfully complete divestitures and other dispositions, our ability to integrate the recent acquisitions of Pall Corporation and Cepheid and achieve the anticipated benefits of such transactions, contingent
    [Show full text]
  • Case No COMP/M.6175 - DANAHER/ BECKMAN COULTER
    EN Case No COMP/M.6175 - DANAHER/ BECKMAN COULTER Only the English text is available and authentic. REGULATION (EC) No 139/2004 MERGER PROCEDURE Article 6(1)(b) NON-OPPOSITION Date: 16/06/2011 In electronic form on the EUR-Lex website under document number 32011M6175 Office for Publications of the European Union L-2985 Luxembourg EUROPEAN COMMISSION Brussels, 16.06.2011 C(2011)4423 In the published version of this decision, some information has been omitted pursuant to Article PUBLIC VERSION 17(2) of Council Regulation (EC) No 139/2004 concerning non-disclosure of business secrets and other confidential information. The omissions are MERGER PROCEDURE shown thus […]. Where possible the information omitted has been replaced by ranges of figures or a ARTICLE 6(1)(b) DECISION general description. To the notifying party: Dear Sir/Madam, Subject: Case No COMP/M.6175 - Danaher/ Beckman Coulter Commission decision pursuant to Article 6(1)(b) of Council Regulation No 139/20041 1. On 6 May 2011, the European Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 by which the undertaking Djanet Acquisition Corp. (USA) controlled by Danaher Corporation (USA) ("Danaher") acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of the undertaking Beckman Coulter, Inc. (USA) ("Beckman") by way of public bid announced on 15 February 2011. Danaher and Beckman are designated hereinafter as the "parties (to the proposed transaction)"2. 1 OJ L 24, 29.1.2004, p. 1 ("the Merger Regulation").
    [Show full text]
  • Journal 2428
    Iris um Oifig Maoine Intleachtúla na hÉireann Journal of the Intellectual Property Office of Ireland Iml. 96 Cill Chainnigh 06 January 2021 Uimh. 2428 CLÁR INNSTE Cuid I Cuid II Paitinní Trádmharcanna Leath Leath Official Notice 1 Official Notice 1 Applications for Patents 3 Applications for Trade Marks 3 Patents Granted 4 Oppositions under Section 43 68 European Patents Granted 5 Application(s) Withdrawn 68 Applications Withdrawn, Deemed Withdrawn or Trade Marks Registered 69 Refused 151 Trade Marks Renewed 69 Request for Grant of Supplementary Protection Application(s) for Leave to Alter Registered Certificate 167 Trade Mark(s) 71 Supplementary Protection Certificate Withdrawn 168 Leave to Alter Registered Trade Mark(s) Supplementary Protection Certificate Rejected 168 Granted 71 Application for Extension of the Duration of a International Registrations under the Madrid Supplementary Protection Certificate 169 Protocol 72 Errata 170 International Trade Marks Protected 93 Cancellations effected for the following goods/services under the Madrid protocol 95 Dearachtaí Designs Information under the 2001 Act Designs Registered 171 The Journal of the Intellectual Property Office of Ireland is published fortnightly. Each issue is freely available to view or download from our website at www.ipoi.gov.ie © Rialtas na hÉireann, 2021 © Government of Ireland, 2021 1 (06/01/2021) Journal of the Intellectual Property Office of Ireland (No. 2428) Iris um Oifig Maoine Intleachtúla na hÉireann Journal of the Intellectual Property Office of Ireland Cuid I Paitinní agus Dearachtaí No. 2428 Wednesday, 6 January, 2021 NOTE: The office does not guarantee the accuracy of its publications nor undertake any responsibility for errors or omissions or their consequences.
    [Show full text]
  • 2018 Annual Report
    2018 Annual Report Danaher 2018 Annual Report Financial Operating Highlights (dollars in millions except per share data and number of associates) 2018 2017 Sales $ 19,893.0 $ 18,329.7 Operating Profit $ 3,403.8 $ 2,990.4 Net Earnings $ 2,650.9 $ 2,469.8 Net Earnings Per Share (diluted) $ 3.74 $ 3.50 Operating Cash Flow $ 4,022.0 $ 3,477.8 Investing Cash Flow $ (2,949.4) $ (843.4) Financing Cash Flow $ (797.4) $ (3,098.5) Capital Expenditures $ (655.7) $ (619.6) Capital Disposals $ 6.3 $ 32.6 Free Cash Flow (Operating Cash Flow less Capital Expenditures plus Capital Disposals) $ 3,372.6 $ 2,890.8 Number of Associates 71,000 67,000 Total Assets $ 47,832.5 $ 46,648.6 Total Debt * $ 9,740.3 $ 10,522.1 Stockholders’ Equity $ 28,226.7 $ 26,367.8 Total Capitalization (Total Debt plus Stockholders’ Equity) $ 37,967.0 $ 36,889.9 * Long-Term Debt ($9,688.5 for 2018 and $10,327.4 for 2017) plus Notes Payable and Current Portion of Long-Term Debt ($51.8 for 2018 and $194.7 for 2017) All financial data set forth in this annual report relates solely to continuing operations unless otherwise indicated. 2018 Annual Report Dear Shareholders, As I begin my 30th year at Danaher, it is humbling to reflect on what our team has achieved over that time and exciting to think about the opportunities that still lie ahead. Financially and strategically, 2018 was an outstanding year. With the Danaher Business System (DBS) as our driving force, we strengthened our footholds in attractive, fast-growing markets and enhanced our competitive positions.
    [Show full text]
  • Beckman Coulter Expanding Operations
    NEWS RELEASE Contacts: Hillary Hunter, Public Relations Phone: (561) 714-7826 E-mail: [email protected] Steve Ernst, Veris Communications Phone: (973) 702-7249 E-mail: [email protected] FOR IMMEDIATE RELEASE Beckman Coulter Life Sciences Expands Particle Characterization Group, Adds Hach Company’s Particle Counting Division Combined Businesses to Offer World-Class Expertise, Service and Solutions INDIANAPOLIS – October 21, 2013 – Beckman Coulter Life Sciences announces it is combining its Particle Characterization business with the Particle Counting business from Hach Company. This move brings together Beckman Coulter’s expertise in cell viability, particle sizing and particle analysis with Hach’s prominence in air and liquid particle counting, and will enable deeper particle characterization solutions, world-class customer support and superior service. In some countries the transition is subject to completing consultation and/or information with certain employee representative bodies. “This is an exciting time in the histories of these two storied enterprises,” said Jennifer Honeycutt, president, Beckman Coulter Life Sciences. “The Coulter, MET ONE and HIAC™ brands helped found the particle counting and characterization industry. Bringing them together allows us to continue to build on the success of these businesses and bring tremendous value to our customers.” Personnel from the particle counting business of Hach will transition into the Beckman Coulter Life Sciences business to work alongside the Particle Characterization team. Combing these two leading, Danaher Corporation-owned life science companies redefines the Beckman Coulter Particle Characterization business and uniquely positions it to provide innovative technologies to a number of important markets. For more information, please visit www.particle.com.
    [Show full text]
  • Appendices Due to Concerns Over the Quality of the Data Collected
    APPENDIX A WSU 2014-19 STRATEGIC PLAN Appendix A: WSU Strategic Plan 2014-15 Strategic Plan 2014-2019 President Elson S. Floyd, Ph.D. Strategic Plan 2014-2019 Introduction The 2014-19 strategic plan builds on the previous five-year plan, recognizing the core values and broad mission of Washington State University. Goals and strategies were developed to achieve significant progress toward WSU’s aspiration of becoming one of the nation’s leading land-grant universities, preeminent in research and discovery, teaching, and engagement. The plan emphasizes the institution’s unique role as an accessible, approachable research institution that provides opportunities to an especially broad array of students while serving Washington state’s broad portfolio of social and economic needs. While providing exceptional leadership in traditional land-grant disciplines, Washington State University adds value as an integrative partner for problem solving due to its innovative focus on applications and its breadth of program excellence. The plan explicitly recognizes the dramatic changes in public funding that have occurred over the duration of the previous strategic plan, along with the need for greater institutional nimbleness, openness, and entrepreneurial activity that diversifies the University’s funding portfolio. In addition, the plan reaffirms WSU’s land-grant mission by focusing greater attention system-wide on increasing access to educational opportunity, responding to the needs of Washington state through research, instruction, and outreach, and contributing to economic development and public policy. While the new plan retains the four key themes of the previous plan, its two central foci include offering a truly transformative educational experience to undergraduate and graduate students and accelerating the development of a preeminent research portfolio.
    [Show full text]
  • EU Top Applicants 2010-2014 Based on Assignees2014 5Yr.Tsv
    EU top applicants 2010-2014 Based on Assignees2014 5yr.tsv table_row ordering_cd 15943 309 13406 105 13407 105 13408 105 13409 105 13410 105 13411 105 13412 105 13413 105 13414 105 13415 105 13416 105 13417 105 13418 105 13419 105 13420 105 13421 105 13422 105 13423 105 13424 105 Page 1 of 1235 09/26/2021 EU top applicants 2010-2014 Based on Assignees2014 5yr.tsv st_country_cd us_or_foreign FRX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) ATX (Foreign) Page 2 of 1235 09/26/2021 EU top applicants 2010-2014 Based on Assignees2014 5yr.tsv state_country_of_origin assignee_name FRANCE IMERJ, LTD. AUSTRIA INFINEON TECHNOLOGIES AG AUSTRIA ~INDIVIDUALLY OWNED PATENT AUSTRIA AMS AG AUSTRIA NXP B.V. AUSTRIA JULIUS BLUM GMBH AUSTRIA BAXTER INTERNATIONAL INC. AUSTRIA EPCOS AG AUSTRIA INFINEON TECHNOLOGIES AUSTRIA AG AUSTRIA MED-EL ELEKTROMEDIZINISCHE GERAETE GMBH AUSTRIA SIEMENS AKTIENGESELLSCHAFT AUSTRIA AVL LIST GMBH AUSTRIA MAGNA POWERTRAIN AG & CO KG AUSTRIA HILTI AKTIENGESELLSCHAFT AUSTRIA BOEHRINGER INGELHEIM INTERNATIONAL GMBH AUSTRIA FRONIUS INTERNATIONAL GMBH AUSTRIA SIEMENS VAI METALS TECHNOLOGIES GMBH AUSTRIA CONTINENTAL AUTOMOTIVE GMBH AUSTRIA INTEL MOBILE COMMUNICATIONS GMBH AUSTRIA MAGNA STEYR FAHRZEUGTECHNIK AG & CO. KG Page 3 of 1235 09/26/2021 EU top applicants 2010-2014 Based on Assignees2014 5yr.tsv CY_2010 CY_2011
    [Show full text]
  • INVESTOR & ANALYST MEETING December 16, 2015
    INVESTOR & ANALYST MEETING December 16, 2015 Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future, are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, deterioration of or instability in the economy, the markets we serve and the financial markets, the impact of our restructuring activities on our ability to grow, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new and enhanced products and services and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our ability to successfully identify, consummate and integrate appropriate acquisitions and successfully complete divestitures and other dispositions, our ability to integrate the recently acquired Pall Corporation and achieve the anticipated benefits of that transaction, our ability to successfully consummate the separation of Danaher into two public companies and realize the anticipated benefits of that transaction, contingent liabilities relating to
    [Show full text]